文献速递妇科

奈拉替尼靶向治疗HER2突变转移性宫颈癌:2期SUMMIT篮式试验最终结果

Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
PubMed 文献 · Gynecol Oncol · 2024-01-11

SUMMIT 2期篮式试验宫颈癌队列最终结果:22例HER2突变晚期/复发宫颈癌患者接受奈拉替尼240 mg/日,确认客观缓解率18.2%(95%CI 5.2-40.3),临床获益率45.5%(95%CI 24.4-67.8),中位缓解持续时间7.6个月(95%CI 5.6-12.3),中位无进展生存期5.1个月(95%CI 1.7-7.2)。作者认为结果支持对部分晚期宫颈癌患者进行二代测序和个体化治疗,并认为需进一步评估奈拉替尼在此场景中的应用。

要点

  • 22例HER2突变转移/复发宫颈癌患者接受奈拉替尼240 mg/日,确认客观缓解率18.2%(95%CI 5.2-40.3)。
  • 临床获益率45.5%(95%CI 24.4-67.8),中位缓解持续时间7.6个月(95%CI 5.6-12.3)。
  • 全部缓解均发生于宫颈管内膜腺癌患者,3级腹泻5例(22.7%),无4级不良事件。

核心结论

  • 奈拉替尼在SUMMIT研究的HER2突变转移性/复发性宫颈癌患者中产生持久缓解和疾病控制。
  • 作者认为这些发现支持对部分晚期宫颈癌患者进行二代测序和个体化治疗。
  • 全部缓解均发生于宫颈管内膜腺癌患者,作者认为需进一步评估奈拉替尼在此场景中的应用。

研究设计与样本

  • 2期SUMMIT篮式试验宫颈癌队列的更新和最终结果。
  • 纳入铂类治疗晚期/复发疾病后进展的HER2突变、转移性或复发性宫颈癌患者。
  • 患者接受奈拉替尼240 mg/日,第1周期强制使用洛哌丁胺;确认客观缓解率为主要终点。
  • 次要终点包括缓解持续时间、临床获益率、无进展生存期和安全性;共入组22例患者。
  • 试验注册号:NCT01953926(ClinicalTrials.gov),2013-002872-42(EudraCT)。

主要发现

  • 22例患者中18例(81.8%)为宫颈管内膜腺癌,既往系统化疗方案中位数为2种(范围1-4)。
  • 最常见HER2变异为S310F/Y突变(n=13;59.1%)。
  • 4例确认部分缓解(客观缓解率18.2%;95%CI 5.2-40.3),6例疾病稳定≥16周(临床获益率45.5%;95%CI 24.4-67.8)。
  • 中位缓解持续时间7.6个月(95%CI 5.6-12.3),中位无进展生存期5.1个月(95%CI 1.7-7.2)。
  • 全级别腹泻(90.9%)、恶心(54.5%)和便秘(54.5%)为最常见不良事件;5例(22.7%)报告3级腹泻;无4级不良事件,无因腹泻停药,2例5级不良事件与奈拉替尼无关:呼吸困难(n=1)和栓塞(n=1)。

临床怎么用

  • 作者认为这些发现支持对部分晚期宫颈癌患者进行二代测序和个体化治疗。
  • 作者认为需进一步评估奈拉替尼在HER2突变转移性/复发性宫颈癌中的应用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: HER2 mutations are associated with poor prognosis and are detected in 3-6% of cervical cancers. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, had activity in several HER2-mutant cancer types in the phase 2 SUMMIT basket study. We present updated and final results from the cervical cancer cohort of SUMMIT. METHODS: Eligible patients had HER2-mutant, metastatic or recurrent cervical cancer progressing after platinum-based treatment for advanced/recurrent disease. Patients received neratinib 240 mg/day; loperamide was mandatory during cycle 1. Confirmed objective response rate (ORR) was the primary endpoint. Duration of response (DoR), clinical benefit rate (CBR), progression-free survival (PFS), and safety were secondary endpoints. RESULTS: Twenty-two patients were enrolled; 18 (81.8%) had endocervical adenocarcinoma; median two prior systemic chemotherapy regimens (range 1-4). The most common HER2 variant was S310F/Y mutation (n = 13; 59.1%). Four patients had confirmed partial responses (ORR 18.2%; 95% CI 5.2-40.3); 6 had stable disease ≥16 weeks (CBR 45.5%; 95% CI 24.4-67.8). Median DoR was 7.6 months (95% CI 5.6-12.3). Median PFS was 5.1 months (95% CI 1.7-7.2). All-grade diarrhea (90.9%), nausea (54.5%), and constipation (54.5%) were the most common adverse events. Five patients (22.7%) reported grade 3 diarrhea. There were no grade 4 adverse events, no diarrhea-related treatment discontinuations, and two grade 5 adverse events, unrelated to neratinib: dyspnea (n = 1) and embolism (n = 1). CONCLUSIONS: Neratinib resulted in durable responses and disease control in patients with HER2-mutant metastatic/recurrent cervical cancer in SUMMIT. These findings support next-generation sequencing and tailored therapy for select patients with advanced cervical cancer. All responses occurred in patients with endocervical adenocarcinoma. Further assessment of neratinib in this setting is warranted. TRIAL REGISTRATION NUMBER: NCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Friedman CF, D'Souza A, Bello Roufai D, et al. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial. Gynecol Oncol. 2024. PMID: 38211393. doi:10.1016/j.ygyno.2023.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。